Dr. Mohamed Sorror’s research is dedicated to improving the care of older, frailer or medically complicated patients with blood cancers. While most people with blood cancers are seniors, studies of new treatments for these diseases routinely exclude them. To solve this problem, Dr. Sorror is gathering evidence and developing decision-making tools to guide the choice of the best treatment for these patients. He leads a large, multi-center, randomized trial testing novel interventions, such as palliative care and dedicated management of individual comorbidities, for patients receiving stem cell transplants to treat blood cancers. Through both clinical and population-based studies, Dr. Sorror aims to optimize the benefits of health care to patients and to society. For example, he is testing, developing and validating methods and tools to predict patient outcomes on treatment, including survival, toxicity and quality of life. He is learning patients’ experiences, preferences and values for cancer treatment. And his trials are generating evidence of which interventions work best for which types of patients and under what circumstances. Notably, he and colleagues developed the first scoring system, now used worldwide, for predicting the risks a blood stem cell transplant poses for a particular patient.